1 Somatostatin (SRIF) is a cyclic tetradecapeptide present in medium-sized aspiny interneurones in the rat striatum. We have previously shown that exogenous SRIF potently stimulates striatal dopamine (DA) release via a glutamate-dependent mechanism. We now report the ability of the selective sst 2 receptor agonist, BIM-23027, to mimic this eect of SRIF. 2 In vivo microdialysis studies were performed in anaesthetized male Wistar rats. In most experiments, compounds were administered by retrodialysis into the striatum for 15 min periods, 90 min and 225 min after sampling commenced, with levels of neurotransmitters being measured by HPLC with electrochemical and¯uorescence detection. 3 BIM-23027 (50 and 100 nM) stimulated DA release with extracellular levels increasing by up to 18 fold. 4 Prior retrodialysis of BIM-23027 (50 nM) abolished the eects of subsequent administration of SRIF (100 nM). 5 The agonist eects of both BIM-23027 and SRIF were abolished by the selective sst 2 receptor antagonist, L-Tyr 8 -CYN-154806 (100 nM). 6 The AMPA/kainate receptor antagonist, DNQX (100 mM), abolished the agonist eects of BIM-23027 as previously shown for SRIF. 7 This study provides evidence that the sst 2 receptor mediates the potent dopamine-releasing actions observed with SRIF in the rat striatum. Dopamine release evoked by both peptides appears to be mediated indirectly via a glutamatergic pathway. Other subtype-speci®c somatostatin receptor ligands were unable to elicit any eects and therefore we conclude that no other somatostatin receptor types are involved in mediating the dopamine-releasing actions of SRIF in the striatum.
Introduction
The cycle tetradecapeptide, somatostatin (SRIF), was originally isolated from ovine hypothalamus in 1973 by Brazeau et al. The neuropeptide and its receptors have a wide distribution in the brain and periphery (Epelbaum et al., 1977; Iversen et al., 1978; Schindler et al., 1996; . Five distinct SRIF receptor genes have been discovered and cloned, and the complementary receptor proteins are termed sst 1 ± 5 , one of which, the sst 2 receptor, has two transcriptional isoforms termed sst 2(a) and sst 2(b) in mouse and rat (Vanetti et al., 1992; Schindler et al., 1999) . These receptors are all composed of seven transmembrane-spanning units and are all coupled to Gproteins.
Within the striatum, SRIF is found in a discrete population of medium-sized aspiny interneurones (*12 ± 25 mm in diameter), which account for 1 ± 2% of the total population of interneurones in this region (Kawaguchi et al., 1995) . These SRIF-containing interneurones also contain neuropeptide Y (Vincent & Johansson, 1983) and neuronal nitric oxide synthase (Kawaguchi et al., 1995) and receive direct glutamatergic cortical inputs (Vuillet et al., 1989) .
We have previously shown that infusions of SRIF by retrodialysis in the rat striatum elevates extracellular levels of dopamine (DA), GABA, aspartate (Asp) and taurine (Tau), in a concentration-dependent manner (Hathway et al., 1998) . We also have demonstrated that this eect is dependent upon elevation of glutamate and that the actions of SRIF are calcium-dependent and tetrodotoxin-sensitive. At present neither in situ hybridization nor immunohistochemical studies have been able to provide evidence of signi®cant concentrations of any SRIF receptor type in the rat striatum, although Dournaud et al. (1998) have shown that some sst 2(a) receptors are present in caudal caudate putamen with a speci®c receptor antibody which labelled SRIF-containing cells. Immunohistochemical studies by Schindler et al. (1997; have reported a very sparse distribution of sst 2(a) and sst 2(b) receptors in the rat striatum, which they speculated were on dopaminergic nigro-striatal terminals. However, from our previous dialysis data we hypothesized that the receptor type(s) that mediates the eects of SRIF in the striatum is located on the terminals of cortico-striatal projection neurones which contain glutamate (Glu; Hathway et al., 1998) . In this study, we have attempted to determine the functional somatostatin receptor type(s) that is responsible for mediating the eects of SRIF by utilising some selective somatostatin receptor ligands and measuring their eects upon changes in the levels of striatal neurotransmitters.
Methods

Animals
Adult male Wistar rats (250 ± 300 g) were used in all experiments. Animals were anaesthetized intraperitoneally with a 25% urethane solution and mounted in stereotaxic apparatus (Kopf Instruments, U.S.A.) via two ear bars and an incisor bar set at 78 above the interaural line. Incisions were made in the scalp, and coordinates for microdialysis probe placement were calculated relative to bregma according to a stereotaxic atlas (Pellegrino et al., 1979) . Microdialysis probes (CMA/12; CMA Microdialysis, Stockholm, Sweden; 0.5 mm o.d., 3 mm membrane length) were placed in the medial portion of the right striatum at the coordinates 2 mm rostral to bregma, 2.5 mm lateral to the midline and 6 mm down from the surface of the brain. Body temperature was maintained using a homeothermic heated blanket (Harvard Apparatus, U.K.) at 378C. All animal use procedures were in strict accordance with the U.K. Home Oce guidelines and speci®cally licensed under the Animals (Scienti®c Procedures) Act 1986.
Microdialysis sampling and HPLC methods
Microdialysis sampling started 90 min after probe implantation. A Krebs-Ringer solution (pH 7.4) was made up with Milli-Q (Waters, Milford, MA, U.S.A.) deionized water (resistivity 18.2 MO cm 71 ) containing (in mM): NaCl 138, CaCl 2 1.5, NaHCO 3 11, KCl 5, MgCl 2 1, and NaH 2 PO 4 1; Neostigmine sulphate (5 mM; Sigma) was also added to enable measurement of acetylcholine (ACh) levels. This solution was passed through the probes at 1.5 ml min 71 using a syringe pump (CMA-10; CMA Microdialysis). Samples were collected from the out¯ow tube of the probe into 500 ml Eppendorf tubes containing 2 ml of 10% acetic acid (v v 71 ) at 15 min intervals using a fraction collector (CMA-142; CMA Microdialysis). A liquid switch (CMA-110; CMA Microdialysis) was placed between the syringe pump and the probe to switch between perfusion solutions without introducing air bubbles into the probe. The dead space between the switch and the end of the out¯ow tubing at the end of the probe was calculated to be 10.5 ml, and this was taken into account when switching between solutions. Collected samples (25 ml) were frozen (7208C) immediately upon collection and subsequently used for HPLC analysis.
The amino acids Glu, Asp, GABA, glycine (Gly), citrulline (Cit), arginine (Arg), and Tau were quanti®ed by HPLC using automated precolumn derivatization with o-phthaldialdehyde (Sigma) performed with a Gilson model 231 autosampler and uorescence detection as previously described (Kendrick et al., 1996) . The detection sensitivity of the system was 2 ± 5 nM with 8 ml of sample derivatized. Arg and Cit were also separated and simultaneously quanti®ed by this method with a detection limit of 4 nM.
DA and 5-HT and their respective metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA), were quanti®ed by HPLC with electrochemical detection (LC4B with a Unijet cell and a 6 mm glassy carbon cell at +0.65 V; Bioanalytical Systems, West Lafayette, IN, U.S.A.). The mobile phase was NaCl 10 mM, sodium acetate 85 mM, octane sulphonic acid 150 mg ml 71 , EDTA 100 mg L 71 and 4% methanol (pH 4.5) and a¯ow rate of 210 ml min 71 was used (Gynkotek M480). The column was a C18 reversed-phase Spherisorb (S3ODS2; Waters, U.K.; 2 mm i.dx 15 cm length). A CMA-200 refrigerated microinjector (CMA Microdialysis) was used to inject the samples (7 ± 10 ml injection volume). The detection sensitivity was 100 ± 200 pM.
At the end of each experiment, rats were killed by cervical dislocation and the brains rapidly dissected and sectioned to con®rm the accuracy of probe placements. Examination of the dissected brains revealed that in all animals the microdialysis probes were localized in the medial portion of the right striatum.
Experimental protocol for concentration-dependent eects of somatostatin receptor ligands
Five dierent receptor ligands were investigated in this study, BIM-23027 (sst 2 receptor agonist; Bell & Reisine, 1993) , CYN-154806 (sst 2 receptor antagonist; Bass et al., 1996) , NNC 26-9100 (sst 4 receptor agonist; Ankersen et al., 1998) , L-362,855 (sst 2,5 receptor agonist; Williams et al., 1997) and BIM-23056 (sst 5 receptor antagonist; Wilkinson et al., 1997) ; these were all applied via the microdialysis probes (retrodialysis). Dialysate samples were collected initially for 90 min to establish baseline values. All of the compounds were dissolved in Krebs-Ringer (containing neostigmine) and retrodialysed for a 15 min period 90 min after the commencement of sampling and once again 135 min later. Between challenges the perfusing solution was changed back to Krebs-Ringer. In experiments using NNC 26-9100, L-362,855 and BIM-23056, three concentrations of each compound were tested (1, 50 and 1000 nM).
In experiments using BIM-23027, three concentrations of the compound were tested 10, 50 and 100 nM. Studies were also performed with BIM-23027 (50 nM) and L-Tyr 8 -CYN-154806 (100 nM) applied together in the ®rst administration and BIM-23027 (50 nM) alone in the second. The actions of BIM-23027 were also investigated in the presence of the ionotropic glutamate receptor antagonists, D,L-2-amino-5-phosphonopentanoic acid (AP5; an NMDA receptor antagonist) and 6,7-dinitroquinoxaline-2,3-dione (DNQX; an a -amino -3 -hydroxy -5 -methylisoxazole -4 -propionic acid (AMPA)/kainate receptor antagonist). Both DNQX (100 mM) and AP5 (100 mM) were retrodialysed singly and together for 90 min before administration of 50 nM BIM-23027; perfusing solutions were then changed to KrebsRinger for 135 min before a second administration of BIM-23027 (50 nM).
A double agonist study was also performed in which BIM-23027 (50 nM) was administered to the striatum 90 min after the commencement of sampling; 100 nM SRIF was then administered 30 min later. In separate experiments to investigate whether CYN-154806 (100 nM) had any agonist actions itself, it was retrodialysed for 15 min, 90 min after the commencement of sampling.
Statistics
In each experiment it was con®rmed that the mean concentrations of substances measured in the four control samples taken before a drug challenge did not dier signi®cantly from one another using a repeated-measures ANOVA. To assess the eects of drugs under the dierent conditions in each animal, the sample taken immediately before the drug administration was de®ned as 100%, and the change from this during the 15-min sample with the drug and that immediately after it were expressed as a percentage. 
Results
Eects of BIM-23027 on striatal neurotransmitter levels
Administration of BIM-23027 into the rat striatum increased levels of DA at the two highest concentrations (Figure 1) . The lowest concentration of BIM-23027 tested, 10 nM, did not signi®cantly increase levels of DA (1.24+0.3 fold) or any of the other transmitters tested. BIM-23027 (50 nM) applied 90 min after the commencement of sampling signi®cantly and potently increased levels of DA by 18.4+9.6 fold (compared with mean baseline value, P50.05). The higher concentration of 100 nM, BIM-23027 also increased the levels of DA (10+8.5 fold; P50.01). Unlike the reported eects of SRIF, BIM-23027 had no signi®cant eects upon any of the other transmitters measured at any concentration (P40.05). The increases in DA levels evoked by BIM-23027 were always con®ned to the sample taken during the 15 min administration period, except for the 50 nM concentration of BIM-23027 where DA levels were also elevated in the subsequent sample (3.5+1.25 fold; P50.05). In all cases when the same concentration of BIM-23027 was repeated 135 min after the ®rst, it did not increase signi®cantly the concentrations of any of the transmitters.
Eects of BIM-23027 upon the actions of SRIF
A 15 min period of administration of BIM-23027 (50 nM) prior to a 15 min infusion of SRIF (100 nM) signi®cantly attenuated the actions of the naturally-occurring peptide. Administration of SRIF to the striatum following the challenge of BIM-23027 did not elicit signi®cant eects upon any striatal neurotransmitter levels (see Figure 2a) . The eects of SRIF (100 nM) upon DA levels were abolished by prior administration of BIM-23027, i.e. 1.0+0.6 fold compared with 28.7+1.5 fold without pre-administration (see Hathway et al., 1998) .
Eects of CYN-154806 upon the actions of BIM-23027 and SRIF
A 15 min period of co-administration of the sst 2 receptor antagonist, CYN-154806 (100 nM), signi®cantly attenuated the actions of BIM-23027 (50 nM). Thus in these experiments, BIM-23027 did not elicit a signi®cant increase in DA (1.5+0.7 fold, P50.05). Nor were there any changes in any of the other neurotransmitters measured (see Figure 3) . In analogous experiments, a 15 min concomitant period of administration of CYN-154806 (100 nM) signi®cantly attenuated the actions of SRIF (100 nM; DA 1.0+0.03 fold, P40.05; Figure 3 ).
Eects of DNQX and AP5 upon the actions of BIM-23027
Retrodialysis of the AMPA/kainate receptor antagonist, DNQX (100 mM), for 90 min prior to a 50 nM application of BIM-23027 abolished the ability of the peptide to elicit increases in DA levels (0.5+0.4 fold compared to 18.4+9.6 fold P50.01; Figure 2b ). The NMDA receptor antagonist AP5 also signi®cantly decreased the amount of DA released in response to administration of BIM-23027 (50 nM; 5.2+2.5 fold, P50.05; Figure 2b ).
Eects of NNC 26-9100, L-362,855 and BIM-23056 on striatal neurotransmitter levels Retrodialysis of NNC 26-9100, the sst 4 receptor agonist (1, 50 and 1000 nM), L-362,855, the sst 5 receptor agonist (1, 50 and 1000 nM), and BIM-23056, the sst 5 receptor antagonist (1, 50 and 1000 nM), did not alter levels of any of the compounds measured (data not shown).
Discussion
The experiments described here have provided the ®rst evidence for a striatal eect of the selective sst 2 receptor agonist, BIM-23027, and hence proof of the existence of functional sst 2 receptors in the rat striatum. This agonist, concentration-dependently increased extracellular levels of DA (but not DOPAC) in the striatum although the concentrationresponse relationship appeared all or none, on the basis of the concentrations studied. No eects upon levels of 5-HT, 5-HIAA, or the amino acid neurotransmitters were seen at any concentration of this compound tested. A second administration of BIM-23027 (50 nM), given 120 min after the ®rst, did not alter signi®cantly the release of DA suggesting that receptor desensitization occurs even at concentrations close to threshold for overt agonist activity. Although BIM-23027 potently increased levels of DA in the striatum, the degree of this eect was less than that observed with SRIF (100 nM) (Hathway et al., 1998) . However, the most potent dose of BIM-23027 used (50 nM), was 50% of the most potent dose of SRIF used (100 nM) and the increases observed with these compounds at these doses were not signi®cantly dierent. As with SRIF, the concentration-response relationship with BIM-23027 is bell-shaped and it may be that BIM-23027 at equivalent doses is able to release DA more potently than SRIF. However, the observation that a second application of this compound is ineective, implying that receptor desensitization occurs, precludes this comparison. It should be noted that neostigmine (5 mM) was included in our perfusing KrebsRinger solution to enable measurement of ACh levels from our dialysates. Removal of this compound from the Krebs-Ringer had no in¯uence upon the eects of the compounds used in this study or upon the levels of neurotransmitters measured, except ACh (data not shown).
The results also show that other somatostatin receptor typeselective ligands, L-Tyr 8 -CYN-154806, NNC 26-9100, L-362, 855, and BIM-23056, had no eect upon levels of any neurotransmitters measured in this study at any concentration tested (Tallent et al., 1996; Wilkinson et al., 1997; Williams et al., 1997; Ankersen et al., 1998) . The lack of eect of the agonists, NNC 26-9100 and L-362,855, rules out a possible involvement of sst 4 or sst 5 receptors respectively. The apparent inactivity of L-362,855 may be surprising in view of known agonist activity at sst 2 receptors (see Chessell et al., 1996; Hicks et al., 1998) . However, it can behave as a partial agonist at somatostatin receptors and may dierentially activate receptor-eector coupling mechanisms compared to SRIF (Williams et al., 1997; Smalley et al., 1998; Sellers et al., 1999) . Alternatively an action of L-362,855 at sst 5 receptors could cause an opposing eect. BIM-23056, which has been reported to be an antagonist at sst 5 receptors also had no eect (Wilkinson et al., 1996; . To examine further whether more than one type of somatostatin receptor might mediate the actions of SRIF, the sst 2 receptor population in the striatum was desensitized by administering BIM-23027 (50 nM) 30 min before SRIF (100 nM). Since SRIF had no subsequent eect on any of the transmitters measured in this paradigm, there is no evidence for the involvement of non-sst 2 receptors. The results also show that BIM-23027-evoked release of DA can be blocked by the presence of the selective sst 2 receptor antagonist, L-Tyr 8 -CYN-154806, as well as by DNQX suggesting that the eect of the synthetic hexapeptide on DA release is caused by activation of sst 2 receptors which mediate the release of Glu from the terminals of glutamatergic corticostriatal projection neurones. An indirect glutamatergic link has also been postulated for SRIF's DA-releasing action in rat striatum (see Hathway et al., 1998) .
The apparent lack of involvement of any other SRIF receptors in mediating striatal neurochemical changes might be thought surprising in view of the widespread distribution of all ®ve SRIF receptors. However, in situ hybridization techniques have been unable to speci®cally identify the particular receptors present in the striatum (Senaris et al., 1994; Schindler et al., 1997) .
The eects of both SRIF and BIM-23027 are antagonized by L-Tyr
-CYN-154806
Further functional evidence for the neurochemical eects of SRIF being mediated solely by the sst 2 receptor was also provided in this study using L-Tyr 8 -CYN-154806, a stereoisomer of the sst 2 receptor antagonist, CYN-154806, reported by Bass et al. (1996) . They reported that CYN-154806 binds to sst 2 receptors expressed in Chinese hamster ovary cells with an anity of 0.3 nM and an ED 50 of 15 nM for antagonism of sst 2 receptor-mediated inhibition of forskolin-stimulated cyclic AMP accumulation in GH4C1 cells (Bass et al., 1996) . The L-isomer has similar potencies and has been used in electrophysiological studies (Hicks et al., 1998) and to antagonize endogenous sst 2 receptors in isolated tissues . Thus it fully reversed the stimulant eects of BIM-23027 upon outwardly rectifying K + currents in anterior cingulate cortical neurones which express the sst 2 receptor and had a similar eect upon submaximal concentrations of either SRIF (100 nM) or L-362,855 (100 nM). In the study described here L-Tyr 8 -CYN-154806 (100 nM) was retrodialysed for the 15 min period during which BIM-23027 was also administered and was found to abolish the DAreleasing actions of BIM-23027. We also showed that application of L-Tyr 8 -CYN-154806 prevented the action of a subsequent administration of BIM-23027, 120 min later. This seems somewhat surprising but may result from accumulation or lack of`wash out' of the antagonist or alternatively BIM-23027 may have caused desensitization of the receptors even in the absence of overt agonist activity. Nevertheless, the ability of L-Tyr 8 -CYN-154806 to abolish the eects of both SRIF and BIM-23027 further supports the conclusion that the sst 2 receptor predominantly or exclusively mediates the neurochemical actions of SRIF in the striatum.
The ability of BIM-23027 to increase DA levels is mediated by a Glu-dependent mechanism Despite much evidence for the involvement of the sst 2 receptor mediating DA release in the striatum, an apparent paradox exists. The full pro®le of neurotransmitter release seen with SRIF (Hathway et al., 1998) was not reproduced with BIM-23027 in this study. The ®rst BIM-23027 (50 nM) administration by retrodialysis increased concentrations of DA by 18 fold, which was not signi®cantly dierent to that observed with SRIF in the previous study (Hathway et al., 1998) . However, in that study, the increases in DA levels evoked by SRIF were accompanied by increases in Glu, Asp, GABA and Tau levels which were not observed with BIM-23027 in this study. It was concluded previously that SRIF mediates its eects upon striatal neurotransmitter levels via a glutamatergic mechanism with levels of Glu increasing 6 fold on administration of 100 nM SRIF (Hathway et al., 1998) . The ability of SRIF to increase DA levels was shown to be abolished by the AMPA/ kainate receptor antagonist, DNQX (Hathway et al., 1998) and in this study, pretreatment of the striatum with DNQX also abolished the eects of BIM-23027. Previously it has been reported that the NMDA receptor antagonist, AP5 (200 mM), abolishes the ability of SRIF (100 nM) to increase amino acid neurotransmitter levels and also signi®cantly decreases the ability of SRIF to release DA (Hathway et al., 1998) . We have now shown that AP5 signi®cantly attenuates the ability of BIM-23027 to release DA. It must therefore be concluded that BIM-23027, like SRIF, mediates its eects via a glutamatergic mechanism although increases in the levels of Glu were not detectable. One obvious explanation might be that BIM-23027 is a partial agonist at sst 2 receptors such that lower amounts of Glu are released but there is no evidence that this is the case in vitro (see Castro et al., 1996; Wyatt et al., 1996) .
Other explanations for the inability to detect changes in Glu levels may be technical or physiological. It may be that BIM-23027 interferes with the derivatization of the primary amino acids by o-phthaldialdehyde (see Hathway et al., 1998) . Indeed it has been shown that addition of known concentrations of BIM-23027 to a solution containing known quantities of all the amino acids does slightly but signi®cantly decrease the levels of these compounds measured (Glu; 195+12 nM compared with 250 nM in the presence and absence of BIM-23027 respectively n=6; Hathway, 1998) . However, the degree of this eect was not sucient to explain completely our inability to measure changes in Glu levels. A greater eciency of the uptake mechanisms in both neurones and glia for the primary amino acids or alternatively a greater rate of metabolism may explain this eect.
In conclusion, this study is the ®rst to attribute a particular function to a speci®c somatostatin receptor in the striatum of the rat brain in vivo. Nevertheless, further investigation of the role of SRIF and SRIF receptor ligands within the striatum is required to gain a full understanding of the role of the endogenous peptide in this brain region. It may be that anaesthesia may have in¯uenced our results, although at present, no data concerning the eects of these compounds in the`freely-moving' animal are available. The fact that both SRIF and BIM-23027 have been shown to potently stimulate an increase in DA release suggests that somatostatinergic tone involving sst 2 receptors may play a physiological role in the control of movement or may be pathophysiologically involved in movement disorders. Hence, the development of drugs which target the sst 2 receptor may be useful in the treatment of neurodegenerative disorders aecting the dopaminergic basal ganglia system such as in Parkinson's Disease.
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